Michael W. Dunne
2018
In 2018, Michael W. Dunne earned a total compensation of $1.1M as Chief Scientific Officer at Iterum Therapeutics plc, a 90% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $166,551 |
|---|---|
| Option Awards | $595,957 |
| Salary | $377,606 |
| Other | $4,902 |
| Total | $1,145,016 |
Dunne received $596K in option awards, accounting for 52% of the total pay in 2018.
Dunne also received $166.6K in non-equity incentive plan, $377.6K in salary and $4.9K in other compensation.
Rankings
In 2018, Michael W. Dunne's compensation ranked 8,519th out of 14,244 executives tracked by ExecPay. In other words, Dunne earned more than 40.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,519 out of 14,244 | 40th |
Division Manufacturing | 3,388 out of 5,765 | 41st |
Major group Chemicals And Allied Products | 1,275 out of 2,128 | 40th |
Industry group Drugs | 1,065 out of 1,817 | 41st |
Industry Pharmaceutical Preparations | 831 out of 1,391 | 40th |
Source: SEC filing on April 25, 2019.
Dunne's colleagues
We found two more compensation records of executives who worked with Michael W. Dunne at Iterum Therapeutics plc in 2018.